| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9145 | Daratumumab | Darzalex | 10 mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2015 | Jan 1, 2017 | In Use | ||
| J9000 | Doxorubicin | Adriamycin | 10 mg | Chemotherapy | Antitumor Antibiotic | Anthracycline | No | 1989 | Jan 1, 1984 | In Use | ||
| J9060 | Cisplatin | Platinol, Platinol-AQ | 10 mg | Chemotherapy | Alkylating Agent | Platinum Compound | No | 1978 | Jan 1, 1984 | In Use | ||
| J9185 | Fludarabine | Fludara | 50 mg | Chemotherapy | Antimetabolite | Purine Analog | No | 1991 | Jan 1, 1994 | In Use | ||
| J1932 | Lanreotide (Cipla) | Lanreotide Acetate | 1mg | Hormonal Therapy | Somatostatin Analog | No | 2021 | Sep 27, 2022 | In Use | |||
| J1626 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 100 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1993 | Jan 1, 2009 | In Use | ||
| J9225 | Histrelin Acetate | Vantas | 50 mg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2008 | In Use | |||
| C9237 | Lanreotide Acetate | Somatuline Depot | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2007 | Jan 1, 2008 | In Use | |||
| J1447 | Tbo-filgrastim | Granix | 1 mcg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2015 | Jan 1, 2016 | In Use | ||
| J9600 | Porfimer | Photofrin | 75 mg | Chemotherapy | Photosensitizing Agent | Cytotoxin | No | 1995 | Jan 1, 1998 | In Use | ||
| J9061 | Amivantamab | Rybrevant | 2mg | Immunotherapy | Monoclonal Antibody | EGFR, MET | No | 2021 | Jan 26, 2022 | In Use | ||
| Q2057 | Afamitresgene autoleucel | Tecelra | per therapeutic dose | Immunotherapy | T Cell Receptor (TCR) | MAGE-A4 | No | 2024 | Mar 26, 2025 | In Use | ||
| J9024 | Atezolizumab, hyaluronidase-tqjs | Tecentriq Hybreza | 5mg | Immunotherapy | Checkpoint Inhibitor | PD-L1 | No | 2024 | Mar 26, 2025 | In Use | ||
| J1442 | Filgrastim | Neupogen, Zarxio | 1 mcg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 1991 | Jan 1, 2016 | In Use | ||
| NA | Imiquimod | Aldara | 5% | Immunotherapy | Immunomodulator | Retinoic Acid Derivative | No | 1997 | In Use | |||
| J9218 | Leuprolide Acetate | Eligard, Lupron Depot, Viadur, Lupron | 1 mg | Hormonal Therapy | GnRH Agonist | No | 1995 | Jan 1, 1997 | In Use | |||
| C9491 | Avelumab | Bavencio | 10 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2017 | Oct 1, 2017 | In Use | ||
| Q5119 | Rituximab-pvvr | Ruxience | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2019 | Jul 1, 2020 | In Use | ||
| J9223 | Lurbinectedin | Zepzelca | 0.1mg | Chemotherapy | Alkylating Agent | Adduct Forming Agent | No | 2020 | Jan 1, 2021 | In Use | ||
| J9341 | Thiotepa (tepylute) | Tepylute | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard /Ethylenimine | No | 2025 | Jul 9, 2025 | In Use | ||
| J9228 | Ipilimumab | Yervoy | 1mg | Immunotherapy | Checkpoint Inhibitor | CTLA-4 | No | 2011 | Jan 1, 2012 | In Use | ||
| J9174 | Docetaxel (beizray) | Beizray | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2024 | Jul 9, 2025 | In Use | ||
| J0897 | Denosumab | Prolia | 1 mg | Immunotherapy | Monoclonal Antibody | RANKL | No | 2010 | Oct 1, 2012 | In Use | ||
| J9301 | Obinutuzumab | Gazyva | 10 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2013 | Jan 1, 2015 | In Use | ||
| J9255 | Methotrexate (Accord) | Methotrexate | 50mg | Chemotherapy | Antimetabolite | Folic Acid Analog | No | 2014 | Dec 7, 2023 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home